Savara Inc Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Savara Inc (SVRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 296.50 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-08-11
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-06-30 was 276.50K shares, a 51.09% increase year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2026-03-31 was 20.00K shares, a 75.76% decline year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-12-31 was 4.75M shares, a 141.85% increase year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-09-30 was 70.00K shares, a 77.05% decline year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 5.08M shares, a 110.85% increase from fiscal 2024.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 2.41M shares, a 7.61% decline from fiscal 2023.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 2.61M shares, a 174.82% increase from fiscal 2022.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 949.00K shares, a 24.08% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 276.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 296.50K shares 10-Q · filed 2026-08-11 | 5.04M shares derived: sum of 3 quarters · filed 2026-08-11 | 5.11M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 20.00K shares 10-Q · filed 2026-05-12 | 4.76M shares derived: sum of 2 quarters · filed 2026-05-12 | 4.83M shares derived: sum of 3 quarters · filed 2026-05-12 | 5.02M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 4.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | 4.82M shares derived: sum of 2 quarters · filed 2026-03-13 | 5.00M shares derived: sum of 3 quarters · filed 2026-03-13 | 5.08M shares 10-K · filed 2026-03-13 |
| 2025-09-30 | 70.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 253.00K shares derived: sum of 2 quarters · filed 2025-11-12 | 335.50K shares 10-Q · filed 2025-11-12 | 2.30M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 183.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 265.50K shares 10-Q · filed 2025-08-13 | 2.23M shares derived: sum of 3 quarters · filed 2025-08-13 | 2.53M shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 82.50K shares 10-Q · filed 2025-05-13 | 2.04M shares derived: sum of 2 quarters · filed 2025-05-13 | 2.35M shares derived: sum of 3 quarters · filed 2025-05-13 | 2.35M shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 1.96M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 2.27M shares derived: sum of 2 quarters · filed 2025-03-27 | 2.27M shares derived: sum of 3 quarters · filed 2025-03-27 | 2.41M shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 305.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 307.50K shares derived: sum of 2 quarters · filed 2024-11-12 | 447.50K shares 10-Q · filed 2024-11-12 | 2.54M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 2.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 142.50K shares 10-Q · filed 2024-08-12 | 2.23M shares derived: sum of 3 quarters · filed 2024-08-12 | 2.30M shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 140.00K shares 10-Q · filed 2024-05-09 | 2.23M shares derived: sum of 2 quarters · filed 2024-05-09 | 2.30M shares derived: sum of 3 quarters · filed 2024-05-09 | 2.55M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 2.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | 2.16M shares derived: sum of 2 quarters · filed 2024-03-07 | 2.41M shares derived: sum of 3 quarters · filed 2024-03-07 | 2.61M shares 10-K · filed 2024-03-07 |
| 2023-09-30 | 70.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 320.00K shares derived: sum of 2 quarters · filed 2023-11-09 | 520.00K shares 10-Q · filed 2023-11-09 | 1.39M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 250.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 450.00K shares 10-Q · filed 2023-08-10 | 1.32M shares derived: sum of 3 quarters · filed 2023-08-10 | 1.40M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 200.00K shares 10-Q · filed 2023-05-15 | 1.07M shares derived: sum of 2 quarters · filed 2023-05-15 | 1.15M shares derived: sum of 3 quarters · filed 2023-05-15 | 1.15M shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 874.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 949.00K shares derived: sum of 2 quarters · filed 2023-03-30 | 949.00K shares derived: sum of 3 quarters · filed 2023-03-30 | 949.00K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 75.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 75.00K shares derived: sum of 2 quarters · filed 2022-11-10 | 75.00K shares 10-Q · filed 2022-11-10 | 1.05M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 0.00 shares 10-Q · filed 2022-08-11 | 975.00K shares derived: sum of 3 quarters · filed 2022-08-11 | 1.15M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-11 | 975.00K shares derived: sum of 2 quarters · filed 2022-05-11 | 1.15M shares derived: sum of 3 quarters · filed 2022-05-11 | |
| 2021-12-31 | 975.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 1.15M shares derived: sum of 2 quarters · filed 2022-03-30 | 1.25M shares 10-K · filed 2022-03-30 | |
| 2021-09-30 | 175.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 275.00K shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 100.00K shares 10-Q · filed 2021-08-12 | |||
| 2020-09-30 | 227.27K shares 10-Q · filed 2021-11-12 | |||
| 2017-03-31 | 72.59K shares 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |